Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | SIRT6 | Q8N6T7 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.55 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.55 |
| ▸ | CRBN | Q96SW2 | 2/20 | 0.55 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.54 |
| ▸ | LGMN | Q99538 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15958457 | 0.84 | MAPT (0.58) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL4553107 | 0.82 | LGMN (0.53) | MAPTALDH1A1POLBAKR1C3LGMN | |
| SCHEMBL12352613 | 0.81 | SMN1; SMN2 (0.53) | MAPTALDH1A1LGMNLMNAKMT2A | |
| SCHEMBL25366550 | 0.80 | SIRT6 (0.67) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL85548 | 0.80 | AKR1C3 (0.71) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL15271381 | 0.79 | SIRT6 (0.81) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL6151230 | 0.79 | SIRT6 (0.81) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL15958475 | 0.79 | CRBN (0.52) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL15958477 | 0.79 | CRBN (0.52) | MAPTSIRT6ALDH1A1POLBADRB1 | |
| SCHEMBL15319242 | 0.79 | POLB (0.65) | MAPTSIRT6ALDH1A1POLBADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12448389-B2 | BRM targeting compounds and associated methods of use | PRELUDE THERAPEUTICS INCORPORATED (US) | 2025-10-21 | — | — | US | disclosed |
| US-20250214945-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-07-03 | — | — | US | disclosed |
| US-20250214987-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION (KR) | 2025-07-03 | — | — | US | disclosed |
| EP-4506346-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | Korea University Research and Business Foundation (KR) | 2025-02-12 | — | — | EP | disclosed |
| EP-4501915-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | Korea University Research and Business Foundation (KR) | 2025-02-05 | — | — | EP | disclosed |
| CN-118974041-A | Thiobenzimidazole derivatives or pharmaceutically acceptable salts thereof and use thereof | 高丽大学校产学协力团 | 2024-11-15 | — | — | CN | disclosed |
| CN-118974021-A | Preparation method of thiobenzimidazole derivative and novel intermediate for same | 高丽大学校产学协力团 | 2024-11-15 | — | — | CN | disclosed |
| WO-2023191533-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | 고려대학교 산학협력단 | 2023-10-05 | — | — | WO | disclosed |
| WO-2023191536-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | 고려대학교 산학협력단 | 2023-10-05 | — | — | WO | disclosed |
| EP-4240743-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | Prelude Therapeutics, Incorporated (US) | 2023-09-13 | — | — | EP | disclosed |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | F2G LTD. | 2010-03-04 | — | — | US | disclosed |
| WO-2008130637-A1 | HYDRAZIDE COMPOUNDS AS THYROID HORMONE RECEPTOR MODULATORS AND USES THEREOF | NEW YORK UNIVERSITY (US) | 2008-10-30 | — | — | WO | disclosed |
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | disclosed |
| US-7405228-B2 | Antibacterial cyano-(substituted)-methylenepiperidinophenyl oxazolidinones targeting multiple ribonucleoprotein sites | WOCKHARDT LIMITED (IN) | 2008-07-29 | — | — | US | disclosed |
| US-7022716-B2 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2003-07-31 | — | — | US | disclosed |
| EP-1301482-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | Wyeth (US) | 2003-04-16 | — | — | EP | disclosed |
| US-6525202-B2 | E.g., substituted (4-amino-5-hydroxyphenyl)-oxy-)piperidinyl thiazolidin-2,4-dione; antidiabetic agents; atherosclerosis, gastrointestinal, metabolic disorders, glaucoma, neurogenetic inflammation, ocular hypertension and frequent urination | WYETH | 2003-02-25 | — | — | US | disclosed |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | WYETH | 2002-03-07 | — | — | US | disclosed |
| WO-2002006232-A1 | CYCLIC AMINE PHENYL BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144326-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPT 565/4885SIRT6 4036/4885ALDH1A1 1091/4885 |
| US-20250214987-A1 | THIOBENZIMIDAZOLE DERIVATIVE PREPARATION METHOD AND NOVEL INTERMEDIATE THEREFOR | WEE1, WEE2, HADHB | MAPT 4632/4885SIRT6 2289/4885ALDH1A1 156/4885 |
| US-20250214945-A1 | THIOBENZIMIDAZOLE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND USE THEREOF | TTBK2, TUBB3, TUBB | MAPT 157/4885SIRT6 2708/4885ALDH1A1 3214/4885 |
| US-20100056511-A1 | 2- [ (2-SUBSTITUTED) -IND0LIZIN-3-YL] -2-OXO-ACETAMIDE DERIVATIVES AS ANTIFUNGAL AGENTS | NAT1, AGXT, CYP1A2 | MAPT 2950/4885SIRT6 1321/4885ALDH1A1 318/4885 |
| US-20020028835-A1 | Cyclic amine phenyl beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | MAPT 565/4885SIRT6 4036/4885ALDH1A1 1091/4885 |
| US-12448389-B2 | BRM targeting compounds and associated methods of use | ADRM1, BRDT, RBX1 | MAPT 1598/4885SIRT6 2398/4885ALDH1A1 4038/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.